Product
R3R01
1 clinical trial
2 indications
Indication
Alport SyndromeIndication
focal segmental glomerulosclerosisClinical trial
A Phase II, Multi-center, Open-Label Study to Assess Safety, Tolerability, Efficacy and Pharmacokinetics of R3R01 in AS Patients With Uncontrolled Proteinuria on ACE/ARB Inhibition and in Patients With Primary Steroid-Resistant FSGCStatus: Recruiting, Estimated PCD: 2025-03-10